Publications

5808 Results

Chemoprevention of cervical cancer with folic acid: A phase III Southwest Oncology Group study

Authors
JM Childers;J Chu;LF Voigt;P Feigl;HK Tamimi;EW Franklin;DS Alberts;FL Meyskens Jr
Journal / Conference
Cancer Epidemiology Biomarkers & Prevention 4:155-159
Year
1995
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8745

Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: An Intergroup study

Authors
GT Budd;S Green;RM O'Bryan;S Martino;MD Abeloff;JJ Rinehart;R Hahn;J Harris;D Tormey;J O'Sullivan;CK Osborne
Journal / Conference
Journal of Clinical Oncology 13(4):831-839
Year
1995
Research Committee(s)
Breast
Study Number(s)
SWOG-8313 (EST 5186)

Quality of life assessment in cancer clinical trials.

Authors
CM Moinpour;M Savage;K Hayden;J Sawyers;C Uchurch
Journal / Conference
Quality of Life in Behavioral Medicine Research :79-95
Year
1995

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An Intergroup study

Authors
M Grever;K Kopecky;MK Foucar;D Head;JM Bennett;RE Hutchison;WEN Corbett;PA Cassileth;T Habermann;H Golomb;K Rai;E Eisenhauer;F Appelbaum;BD Cheson
Journal / Conference
Journal of Clinical Oncology 13(4):974-982
Year
1995
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8691 (INT-0073)

A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid b-cell subcategories: A Southwest Oncology Group study.

Authors
RI Fisher;S Dahlberg;BN Nathwani;PM Banks;TP Miller;TM Grogan
Journal / Conference
Blood 85(4):1075-1082
Year
1995
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-7204/7205, SWOG-7426/7427, SWOG-7713/14

Design of the prostate cancer prevention trial (PCPT)

Authors
P Feigl;B Blumenstein;I Thompson;J Crowley;M Wolf;BS Kramer;CA Coltman Jr;OW Brawley;LG Ford
Journal / Conference
Controlled Clinical Trials 16:150-163
Year
1995
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

CA-125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer: A Southwest Oncology Group (SWOG) study.

Authors
PY Liu;DS Alberts;M Federico;EV Hannigan;DJ Garcia;ML Rothenberg;RT Dorr
Journal / Conference
ASCO 14:266(#735)
Year
1995
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8412

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report.

Authors
CG Moertel;TR Fleming;JS Macdonald;DG Haller;JA Laurie;CM Tangen;JS Ungerleider;WA Emerson;DC Tormey;JH Glick;MH Veeder;JA Mailliard
Journal / Conference
Annals of Internal Medicine 122(5):321-326
Year
1995
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-8591(NCI Intergroup #0035)

Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases

Authors
CP Leith;IM Chen;KJ Kopecky;FR Appelbaum;DR Head;JE Godwin;JK Weick;CL Willman
Journal / Conference
Blood 86(6):2329-2342
Year
1995
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600, SWOG-9031

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study.

Authors
FL Meyskens Jr;KJ Kopecky;CW Taylor;RD Noyes;RJ Tuthill;EM Hersh;LG Feun;JH Doroshow;LE Flaherty;VK Sondak
Journal / Conference
Journal of the National Cancer Institute 87(22):1710-1713
Year
1995
Research Committee(s)
Melanoma
Study Number(s)
SWOG-8642